HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Nov.3)-Share Price Correction,Valuable Shortcut,Globalization Vs Innovation

Interpretation of China’s Central Financial Work Conference – the Big Changes and the Outlook

CanSino Biologics (6185.HK/688185.CH) 23Q3 - Some Positive Business Progress Worth the Attention

GLP-1 Drugs – Are They Dessert or Time Bomb to Your Portfolio?

Pre-IPO WuXi XDC - The Beautiful Story and the Truth Behind

China's Weight Loss Drug Market – The Investment Opportunities and the Risks Behind

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

WuXi XDC Cayman  / Equity Capital Markets

<ul>
<li>We've seen increasing global cooperation for ADC pipelines. However, licensing deals alone cannot be used as the only basis for judgment. We still need to wait for solid clinical evidence.</li>
<li>ADCs are far less "general and popularized" than PD-1. If compare ADC with GLP-1s, the difference is more obvious.How big the real market is for ADC is a question mark.</li>
<li>WuXi XDC’s share price could perform well after IPO due to positive sentiments towards ADC, but whether its long-term valuation would be higher than peers remains to be seen.  </li>
</ul>


We've seen increasing global cooperation for ADC pipelines. However, licensing deals alone cannot be used as the only basis for judgment. We still need to wait for solid clinical evidence.
ADCs are far less "general and popularized" than PD-1. If compare ADC with GLP-1s, the difference is more obvious.How big the real market is for ADC is a question mark.
WuXi XDC’s share price could perform well after IPO due to positive sentiments towards ADC, but whether its long-term valuation would be higher than peers remains to be seen.  


Pre-IPO WuXi XDC (PHIP Updates) - Some Points Worth the Attention